AB0-incompatible living donor kidney transplantation: the long-term outcomes

Cover Page

Cite item

Abstract

Background: AB0-incompatible kidney transplantation is one of the ways to effectively expand the pool of living donors. In Russia, this technology has been used for more than 10 years, but until now there have been no reports on its long-term results. Aim: To evaluate the short- and long-term outcomes of the living-related AB0-incompatible kidney transplantations. Materials and methods: We analyzed the results of 49 consecutive AB0-incompatible kidney transplantations, performed from 2011 to 2017. Preoperative management of recipients included administration of rituximab and intravenous immunoglobulin, plasmapheresis and/or selective immunoadsorption, and combination of tacrolimus, mycophenolates and steroids. The target of anti-A/B antibody levels were is 1:8. All patients received standard immunosuppression after transplantation. Results: At baseline, median anti-A/B titer was 1:16 (1:2 to 1:1024) for IgM and 1:4 (0 to 1:512) for IgG. Median rituximab dose was 286 mg/m2 (range, from 94 to 396). To achieve target antibody levels, up to 10 plasmapheresis and/or immunoadsorption sessions (median, 2) were required. There were no deaths during the follow-up. Five grafts were lost, one of them due to hyperacute rejection. The incidence of biopsy-proven rejection was 6%. One-, three and six-year graft survival was 94%, 90% and 80%, respectively. Conclusion: Kidney transplantation across the AB0-incompatibility barrier is a  safe, successful and reasonable option to reduce the organ shortage. 

About the authors

Ya. G. Moysyuk

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: moysyuktrans@list.ru

MD, PhD, Professor, Chief Research Fellow, Abdominal Surgery Unit, Department of Hepatology

61/2 Shchepkina ul., 129110, Moscow

Tel.: +7 (964) 640 86 16

Russian Federation

A. I. Sushkov

Burnasyan Federal Medical Biophysical Center

Email: fake@neicon.ru

MD, PhD, Head of New Surgical Technologies Laboratory, Surgery and Transplantation Center

 

23 Marshala Novikova ul., Moscow, 123098, Russian Federation

Russian Federation

References

  1. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest. 1955;34(2):327–82. doi: 10.1172/JCI103085.
  2. Murray JE, Merrill JP, Dammin GJ, Dealy JB Jr, Walter CW, Brooke MS, Wilson RE. Study on transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery. 1960;48:272–84.
  3. Starzl TE, Marchioro TL, Holmes JH, Hermann G, Brittain RS, Stonington OH, Talmage DW, Waddell WR. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery. 1964;55:195–200.
  4. Cook DJ, Graver B, Terasaki PI. ABO incompatibility in cadaver donor kidney allografts. Transplant Proc. 1987;19(6):4549–52.
  5. Slapak M, Naik RB, Lee HA. Renal transplant in a patient with major donor-recipient blood group incompatibility: reversal of acute rejection by the use of modified plasmapheresis. Transplantation. 1981;31(1):4–7.
  6. Squifflet JP, De Meyer M, Malaise J, Latinne D, Pirson Y, Alexandre GP. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp Clin Transplant. 2004;2(1):208–13.
  7. Alexandre GP, Squifflet JP, De Bruyère M, Latinne D, Reding R, Gianello P, Carlier M, Pirson Y. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987;19(6):4538–42.
  8. Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y; Japanese ABO-Incompatible Kidney Transplantation Committee. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant. 2004;4(7):1089–96. doi: 10.1111/j.1600-6143.2004.00464.x.
  9. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation. 2003;76(4):730–1. doi: 10.1097/01. TP.0000078622.43689.D4.
  10. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant. 2005;5(1):145–8. doi: 10.1111/j.1600-6143.2004.00653.x.
  11. Wilpert J, Geyer M, Pisarski P, Drognitz O, Schulz-Huotari C, Gropp A, Goebel H, Gerke P, Teschner S, Walz G, Donauer J. On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorptions after ABO-incompatible kidney transplantation. Nephrol Dial Transplant. 2007;22(10):3048–51. doi: 10.1093/ndt/ gfm460.
  12. Shirakawa H, Ishida H, Shimizu T, Omoto K, Iida S, Toki D, Tanabe K. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant. 2011;25(6):878– 84. doi: 10.1111/j.1399-0012.2010.01384.x.
  13. Chung BH, Hong YA, Sun IO, Piao SG, Kim JI, Moon IS, Choi BS, Park CW, Kim YS, Yang CW. Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation. Ren Fail. 2012;34(8):974–9. doi: 10.3109/0886022X.2012.700892.
  14. Okumi M, Toki D, Nozaki T, Shimizu T, Shirakawa H, Omoto K, Inui M, Ishida H, Tanabe K. ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management. Am J Transplant. 2016;16(3): 886–96. doi: 10.1111/ajt.13502.
  15. Gelpi R, Cid J, Lozano M, Revuelta I, Sanchez-Escuredo A, Blasco M, de Souza E, Esforzado N, Torregrosa JV, Cofán F, Ricart MJ, Campistol JM, Oppenheimer F, Diekmann F. Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers. Transplant Proc. 2015;47(8):2340–3. doi: 10.1016/j.transproceed.2015.08.021.
  16. Lo P, Sharma A, Craig JC, Wyburn K, Lim W, Chapman JR, Palmer SC, Strippoli GF, Wong G. Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis. Transplantation. 2016;100(4):933–42. doi: 10.1097/ TP.0000000000000933.
  17. Barnett AN, Manook M, Nagendran M, Kenchayikoppad S, Vaughan R, Dorling A, Hadjianastassiou VG, Mamode N. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation. Transpl Int. 2014;27(2):187–96. doi: 10.1111/tri.12234.
  18. Горяйнов ВА, Каабак ММ, Бабенко НН, Шишло ЛА, Морозова ММ, Рагимов АА, Дашкова НГ, Салимов ЭЛ. Аллотрансплантация почек от АВ0-несовместимых доноров. Хирургия. Журнал им. Н.И. Пирогова. 2013;(12): 67–72.
  19. Мойсюк ЯГ, Сушков АИ, Пулькова НВ, Абрамов ВЮ, Куприянова АГ, Морозов БН, Порунова АК, Образцова НП, Адамова ИЮ, Готье СВ. Первый отечественный опыт применения иммуноадсорбции при ABO-несовместимой трансплантации почки от живого родственного донора. Вестник трансплантологии и искусственных органов. 2011;13(4):6–18. doi: 10.15825/1995- 1191-2011-4-6-18.
  20. Сушков АИ, Мойсюк ЯГ. Динамика титров анти-A/B-антител в течение предоперационного кондиционирования и после ABO-несовместимой трансплантации почки от живого донора. Трансплантология. 2011;(2–3):48–53.
  21. Сушков АИ, Боровкова НВ, Доронина НВ, Мойсюк ЯГ. Успешная ABO-несовместимая трансплантация почки от живого родственного донора пациенту высокого иммунологического риска. Вестник трансплантологии и искусственных органов. 2012;14(2):63–71. doi: 10.15825/1995-1191-2012-2-63-71.
  22. Сушков АИ, Шаршаткин АВ, Азаренкова ОВ, Ефимкин АС, Малахов АГ, Сайдулаев ДА, Чичкин ИС, Илжанов МИ, Кандидова ИЕ, Квадратова НГ, Мойсюк ЯГ. Преодоление барьера несовместимости по группе крови при трансплантации почки от родственного донора. Нефрология и диализ. 2013;15(4): 286–92.
  23. Сушков АИ, Мойсюк ЯГ. Трехлетний опыт выполнения AB0-несовместимых трансплантаций почки. Трансплантология. 2014;(2):26– 30. doi: 10.23873/2074-0506-2014-0-2-26-30.
  24. Готье СВ, Мойсюк Я.Г., ред. Трансплантология. Фармакотерапия без ошибок (руководство для врачей). М.: Е-ното; 2014. 432 с.
  25. Kim MH, Jun KW, Hwang JK, Kim JI, Chung BH, Choi BS, Kim YS, Yang CW, Moon IS. Risk factors for postoperative bleeding in ABO-incompatible kidney transplantation. Clin Transplant. 2015;29(4):365–72. doi: 10.1111/ctr.12525.
  26. de Weerd AE, van Agteren M, Leebeek FW, Ijzermans JN, Weimar W, Betjes MG. ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption. Transpl Int. 2015;28(1): 25–33. doi: 10.1111/tri.12412.
  27. Schachtner T, Stein M, Reinke P. ABO desensitization affects cellular immunity and infection control after renal transplantation. Transpl Int. 2015;28(10):1179–94. doi: 10.1111/tri.12616.
  28. Böhmig GA, Farkas AM, Eskandary F, Wekerle T. Strategies to overcome the ABO barrier in kidney transplantation. Nat Rev Nephrol. 2015;11(12): 732–47. doi: 10.1038/nrneph.2015.144.
  29. Kumlien G, Wilpert J, Säfwenberg J, Tydén G. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation. 2007;84(12 Suppl):S17–9. doi: 10.1097/01. tp.0000296019.85986.af.
  30. Bentall A, Regan F, White J, Milkins C, Rowley M, Ball S, Briggs D. No progress in ABO titer measurement: time to aim for a reference? Transplantation. 2014;97(3):e19–21. doi: 10.1097/01.TP.0000438210.27218.9e.
  31. Kobayashi T, Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation. 2006;13(2):136–40. doi: 10.1111/j.1399-3089.2006.00296.x.
  32. Bröcker V, Pfaffenbach A, Habicht A, Chatzikyrkou C, Kreipe HH, Haller H, Scheffner I, Gwinner W, Zilian E, Immenschuh S, Schwarz A, Horn PA, Heinemann FM, Becker JU. Beyond C4d: the ultrastructural appearances of endothelium in ABO-incompatible renal allografts. Nephrol Dial Transplant. 2013;28(12):3101–9. doi: 10.1093/ndt/gft373.
  33. Ushigome H, Okamoto M, Koshino K, Nobori S, Okajima H, Masuzawa N, Urasaki K, Yoshimura N. Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation. Clin Transplant. 2010;24 Suppl 22:16–21. doi: 10.1111/j.1399- 0012.2010.01278.x.
  34. Мойсюк ЯГ, Сушков АИ, Шаршаткин АВ, Бикбов БТ, Азаренкова ОВ. Современные технологии и клинические исследования в трансплантации почки. Вестник трансплантологии и искусственных органов. 2014;16(3):63–75. doi: 10.15825/1995-1191- 2014-3-63-75.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2018 Moysyuk Y.G., Sushkov A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies